A Phase 1 interventional study of [14C]Ulonivirine in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to learn how [14C]ulonivirine moves through a healthy person's body over time. Researchers will study how [14C]ulonivirine is absorbed by the body, broken down by the body, and how it leaves the body.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria include but are not limited to:
Key Exclusion Criteria include but are not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants receive a single oral dose of \[14C\]ulonivirine on Day 1.
Drug: [14C]Ulonivirine
Oral Solution
Also known as: [14C]ULO, [14C]MK-8507
Cumulative Percentage of Total Radioactivity Recovered (FE) from Urine and Feces
Urine and fecal samples will be collected to determine the cumulative percentage of radioactivity recovered from both urine and feces.
Time frame: At designated timepoints (up to approximately 5 weeks postdose)
FE from Urine
Urine samples will be collected to determine the percent of total radioactivity recovered from urine.
Time frame: At designated timepoints (up to approximately 5 weeks postdose)
FE from Feces
Fecal samples will be collected to determine the percent of total radioactivity recovered from feces.
Time frame: At designated timepoints (up to approximately 5 weeks postdose)
Cumulative Amount of Radioactivity Recovered from Urine
Urine samples will be collected to determine the cumulative amount of radioactivity recovered from urine.
Time frame: At designated timepoints (up to approximately 5 weeks postdose)
Percent of Total Radioactive Dose Recovered from Urine
Urine samples will be collected to determine the percent of the total radioactive dose recovered from urine.
Time frame: At designated timepoints (up to approximately 5 weeks postdose)
Cumulative Amount of Radioactivity Recovered from Feces
Fecal samples will be collected to determine the cumulative amount of radioactivity recovered from feces.
Time frame: At designated timepoints (up to approximately 5 weeks postdose)
Percent of Total Radioactive Dose Recovered from Feces
Fecal samples will be collected to determine the percent of the total radioactive dose recovered from feces.
Time frame: At designated timepoints (up to approximately 5 weeks postdose)
Plasma Ulonivirine: Area Under the Concentration-Time Curve from Time 0 to Time of the Last Concentration (AUC0-last)
Plasma samples will be collected to determine the AUC0-last of ulonivirine.
Time frame: At designated timepoints (up to approximately 2 weeks postdose)
Plasma Ulonivirine: Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf)
Plasma samples will be collected to determine the AUC0-inf of ulonivirine.
Time frame: At designated timepoints (up to approximately 2 weeks postdose)
Plasma Ulonivirine: Maximum Observed Concentration (Cmax)
Plasma samples will be collected to determine the Cmax of ulonivirine.
Time frame: At designated timepoints (up to approximately 2 weeks postdose)
Plasma Ulonivirine: Concentration at 168 Hours Postdose (C168)
Plasma samples will be collected to determine the C168 of ulonivirine.
Time frame: At approximately 1 week postdose
Plasma Ulonivirine: Terminal Half-life (t1/2)
Plasma samples will be collected to determine the t1/2 of ulonivirine.
Time frame: At designated timepoints (up to approximately 2 weeks postdose)
Plasma Ulonivirine: Time of Maximum Observed Concentration (Tmax)
Plasma samples will be collected to determine the Tmax of ulonivirine.
Time frame: At designated timepoints (up to approximately 2 weeks postdose)
Ratio of Ulonivirine to Total Plasma Radioactivity: AUC0-last (ulonivirine)/ AUC0-last (total radioactivity)
Plasma samples will be collected to determine the ratio of ulonivirine to total plasma radioactivity: AUC0-last (ulonivirine)/ AUC0-last (total radioactivity)
Time frame: At designated timepoints (up to approximately 5 weeks postdose)
Plasma Total Radioactivity: AUC0-last
Plasma samples will be collected to determine the AUC0-last of total radioactivity.
Time frame: At designated timepoints (up to approximately 5 weeks postdose)
Plasma Total Radioactivity: AUC0-inf
Plasma samples will be collected to determine the AUC0-inf of total radioactivity.
Time frame: At designated timepoints (up to approximately 5 weeks postdose)
Plasma Total Radioactivity: Cmax
Plasma samples will be collected to determine the Cmax of total radioactivity.
Time frame: At designated timepoints (up to approximately 5 weeks postdose)
Plasma Total Radioactivity: C168
Plasma samples will be collected to determine the C168 of total radioactivity.
Time frame: At approximately 1 week postdose
Plasma Total Radioactivity: t1/2
Plasma samples will be collected to determine the t1/2 of total radioactivity.
Time frame: At designated timepoints (up to approximately 5 weeks postdose)
Plasma Total Radioactivity: Tmax
Plasma samples will be collected to determine the Tmax of total radioactivity.
Time frame: At designated timepoints (up to approximately 5 weeks postdose)
Total Number of Metabolites in Plasma that Represent at least 10% of the Dose of Radioactivity
Plasma samples will be collected at pre-specified timepoints and used to determine the total number of metabolites that represent at least 10% of the dose of radioactivity. Metabolites will be determined using liquid scintillation and high-resolution mass spectrometry.
Time frame: At designated timepoints (up to approximately 5 weeks postdose)
Total Number of Metabolites in Urine that Represent at least 10% of the Dose of Radioactivity
Urine samples will be collected at pre-specified timepoints and used to determine the total number of metabolites that represent at least 10% of the dose of radioactivity. Metabolites will be determined using liquid scintillation and high-resolution mass spectrometry.
Time frame: At designated timepoints (up to approximately 5 weeks postdose)
Total Number of Metabolites in Feces that Represent at least 10% of the Dose of Radioactivity
Fecal samples will be collected at pre-specified timepoints and used to determine the total number of metabolites that represent at least 10% of the dose of radioactivity. Metabolites will be determined using liquid scintillation and high-resolution mass spectrometry.
Time frame: At designated timepoints (up to approximately 5 weeks postdose)
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 5 weeks
Number of Participants Who Discontinue the Study Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 5 weeks
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Sep 2025 to primary completion in Nov 2025, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ulonivirine